Aclaris Therapeutics, Inc. (ACRS) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 13 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for ACRS is $10.00, representing a +155.1% upside from the current price of $3.92. Price targets range from a low of $10.00 to a high of $10.00.
